Creating immune organoids to study pediatric cancers
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
This study is trying to create mini immune systems from kids' tissues to see how they respond to different types of pediatric cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | N/A to 25 Years |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 2 sites (Villejuif and 1 other locations) |
| Trial ID | NCT05890781 on ClinicalTrials.gov |
What this trial studies
This study aims to engineer immune organoids from tissues of pediatric patients using induced-pluripotent stem cells (iPSC). By utilizing skin biopsies, fresh tumor samples, blood samples, healthy tissue, and cerebrospinal fluid, the research seeks to better understand the immune response in various pediatric cancers, including brain tumors, kidney tumors, neuroblastoma, and sarcomas. The approach focuses on leveraging patient-derived materials to create organoids that can mimic the tumor environment and immune interactions. This innovative methodology may provide insights into treatment responses and disease mechanisms.
Who should consider this trial
Good fit: Ideal candidates for this study are pediatric patients aged 25 years or younger with a medical suspicion or diagnosis of brain tumors, renal tumors, neuroblastoma, or sarcomas.
Not a fit: Patients with histologies not specified in the inclusion criteria or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for pediatric cancers.
How similar studies have performed: While the approach of engineering immune organoids is innovative, similar studies have shown promise in understanding cancer biology and treatment responses, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision
Where this trial is running
Villejuif and 1 other locations
- Gustave Roussy — Villejuif, France (Recruiting)
- Hopital Necker — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Study coordinator: Claudia PASQUALINI, MD
- Email: claudia.pasqualini@gustaveroussy.fr
- Phone: +33 (0)1 42 11 55 31
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.